Steroid-Induced Psychosis: Emergency Recognition and Management

Imagine a patient who was perfectly calm when they arrived at the hospital for routine treatment of an autoimmune flare. Within 48 hours, they are screaming that nurses are trying to poison them, pacing the hallway with terrifying agitation, or staring blankly into space, completely detached from reality. This isn't a sudden onset of schizophrenia. It is likely Steroid-Induced Psychosis, a severe psychiatric adverse effect triggered by corticosteroids. For clinicians in emergency departments and intensive care units, missing this diagnosis can lead to unnecessary restraints, inappropriate long-term psychiatric medications, and dangerous delays in treating the underlying cause.

Corticosteroids are life-saving drugs used to manage inflammation, asthma, lupus, and organ rejection. But they carry a hidden risk. Research shows that between 2% and 60% of patients exposed to these powerful anti-inflammatories develop psychiatric symptoms. The incidence of severe syndromes like psychosis sits around 6%. The higher the dose, the higher the danger. A landmark study found that while 4.6% of patients taking more than 40 mg of prednisone daily developed symptoms, that number skyrocketed to 18.4% for those on doses exceeding 80 mg per day. Recognizing this link early is not just about comfort; it is about safety and preventing permanent psychological harm.

Spotting the Early Warning Signs

You cannot treat what you do not see. The challenge with steroid-induced psychosis is that it mimics other conditions. However, the timeline is your most valuable diagnostic tool. Symptoms typically emerge within the first five days of starting therapy or increasing the dose. If a patient has been stable on a low dose for months, sudden psychosis is less likely to be steroid-related unless there was a recent spike in dosage.

Early indicators are often subtle and easily dismissed as general confusion or stress. Look for perplexity, restlessness, and mild agitation. These can quickly escalate into full-blown mania or psychosis featuring hallucinations and delusions. Interestingly, the type of symptom often depends on the duration of treatment. Patients on short-term, high-dose bursts are more prone to mania-euphoria, racing thoughts, and grandiosity. Those on long-term maintenance therapy are more likely to develop depression or cognitive impairment. By the time frank psychosis appears, the window for easy intervention has narrowed, making early vigilance critical.

Ruling Out the Mimics

Before labeling a patient’s behavior as steroid-induced, you must rule out everything else. The DSM-5 requires strict exclusion of alternative causes. In an emergency setting, metabolic chaos is a common culprit. Steroids themselves can cause hyperglycemia (high blood sugar) and electrolyte imbalances, both of which can induce delirium and confusion. Infections, hypoglycemia, brain tumors, or withdrawal from alcohol or benzodiazepines can present with identical psychiatric symptoms.

A thorough medical evaluation is non-negotiable. Check blood glucose levels immediately. Run a comprehensive metabolic panel to assess electrolytes. Review the patient’s medication list for other psychotropic drugs or substances that might interact. Only after you have excluded these physiological triggers should you attribute the psychosis to the corticosteroids. This step prevents misdiagnosis and ensures that if the patient has a sepsis-induced encephalopathy, for example, they receive the correct antibiotic and supportive care rather than just antipsychotics.

Immediate Safety and De-escalation

When a patient becomes acutely psychotic, their safety-and the safety of staff-is the immediate priority. Agitation can lead to violence, self-harm, or accidental removal of vital lines and tubes. The first line of defense is always behavioral de-escalation. Speak calmly, reduce environmental stimuli, and ensure a quiet, safe space. Physical restraints should be considered only as a last resort when all other methods fail and there is an imminent threat of harm, as they can exacerbate agitation and cause physical injury.

If verbal de-escalation fails, pharmacological sedation is necessary. The goal is rapid control with minimal side effects. Oral disintegrating tablets of olanzapine (2.5-20 mg/day) or risperidone (1-4 mg/day) are effective for cooperative patients. For those who refuse oral medication or are too agitated, intramuscular (IM) injections are required. IM olanzapine alone or IM haloperidol (2-5 mg) combined with lorazepam (1-2 mg) provides quick stabilization. Be cautious with haloperidol, as it carries a risk of extrapyramidal symptoms (EPS), such as muscle stiffness or dystonia. Co-administering benztropine or diphenhydramine can mitigate these risks. Remember, the aim is sedation and symptom control, not deep unconsciousness.

The Cornerstone Treatment: Tapering the Dose

Antipsychotics manage the symptoms, but reducing the steroid treats the cause. The definitive management for steroid-induced psychosis is lowering the corticosteroid dose. Evidence suggests that tapering the dose to below 40 mg/day of prednisone (or an equivalent dose of dexamethasone) resolves symptoms in approximately 92% of cases. This high success rate makes tapering the single most important intervention.

However, tapering is not without risks. Many patients are on steroids for serious underlying conditions like rheumatoid arthritis or lupus nephritis. Abruptly stopping the drug can trigger a catastrophic flare of the primary disease or adrenal insufficiency. You must work closely with the prescribing specialist. The strategy is to find the lowest possible dose that still controls the inflammatory condition while alleviating psychiatric symptoms. In some cases, switching from a potent steroid like dexamethasone to one with fewer CNS side effects, such as hydrocortisone, may be beneficial, though evidence here is mixed. The key is communication: the psychiatrist and the internist must agree on a balanced tapering schedule.

Pharmacological Support When Tapering Isn't Enough

What if the patient cannot tolerate any reduction in steroids? In these rare but challenging scenarios, where the underlying disease is life-threatening and requires high-dose immunosuppression, pharmacological management becomes the primary long-term strategy. No medication is FDA-approved specifically for steroid-induced psychosis, so clinicians rely on off-label use of standard antipsychotics.

Low-dose antipsychotics are preferred. Haloperidol (0.5-1 mg/day), olanzapine (2.5-20 mg/day), and risperidone (1-4 mg/day) are commonly used. Studies show these doses are sufficient to resolve symptoms within days to weeks. Avoid the temptation to use high doses typical for first-episode schizophrenia; patients with substance-induced psychosis are often more sensitive to medication side effects. Over-sedation can complicate the clinical picture and increase fall risk.

Lithium is another option, particularly for preventing steroid-induced mania. It has shown efficacy in prophylactic settings but requires careful monitoring due to its narrow therapeutic index and potential side effects. Mood stabilizers like valproic acid or carbamazepine may also be considered, especially if manic features dominate. Antidepressants are generally avoided in the acute phase as they can worsen mania, but they may be useful later if depressive symptoms persist after the psychosis resolves.

Building Better Emergency Protocols

Despite clear guidelines, practice varies widely. A survey of emergency physicians revealed that while most recognize steroids as a trigger, many fail to follow recommended tapering protocols or prescribe excessively high doses of antipsychotics. To improve outcomes, hospitals need standardized protocols. This includes automatic screening for psychiatric symptoms in patients starting high-dose steroids, clear pathways for rapid consultation with liaison psychiatry, and education for nursing staff on early signs of agitation.

Future advancements promise better prevention. Ongoing research aims to identify genetic biomarkers that predict susceptibility to steroid-induced psychosis. Imagine a future where a simple blood test before starting treatment could tell you which patients are at high risk, allowing for preemptive mood stabilizer therapy or lower initial steroid doses. Until then, vigilance, rapid assessment, and collaborative care remain our best tools.